UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December 31, 2021~~September 30, 2022

☐

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the transition period from ___________ to ___________

Commission file number 001-34426

Astrotech Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware	91-1273737
State or Other Jurisdiction of Incorporation or Organization	I.R.S. Employer Identification No.

2105 Donley Drive, Suite 100, Austin, Texas	78758
Address of Principal Executive Offices	Zip Code	~~Zip Code~~

(512) 485-9530

Registrant’s Telephone Number, Including Area Code

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

ASTC

NASDAQ Stock Market, LLC

Table of Contents

~~NASDAQ Stock Market, LLC~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	☐	Accelerated filer	☐
Non-accelerated filer	☒	☒	Smaller reporting company	☒
Emerging growth company	☐

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of ~~February 7,~~November 10, 2022, the number of shares of the registrant’s common stock outstanding was: ~~49,569,113.~~

50,714,410.

Table of Contents

ASTROTECH CORPORATION AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

Table of Contents

PART I: FINANCIAL INFORMATION

ITEM 1.Condensed Consolidated Financial Statements

ASTROTECH CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

							*September 30,*			*June 30,*
	December 31, 2021			June 30, 2021			*2022*			*2022*
	(Unaudited)			(Note)			(Unaudited)			(Note)
Assets
Current assets
Cash and cash equivalents	$	30,170		$	35,936		$	18,273		$	26,453
Short-term investments		27,106			27,351			30,675			26,173
Accounts receivable		92			5			38			56
Cost and estimated revenue in excess of billings								—			2
Inventory, net:
Raw materials		1,135			1,056			925			864
Work-in-process		2			147			76			136
Finished goods		277			297			465			518
Prepaid expenses and other current assets		516			318			901			748
Total current assets		59,298			65,110			51,353			54,950
Property and equipment, net		870			263			1,350			1,098
Operating leases, right-of-use assets, net		206			249			140			162
Other assets		11			11			11			11
Total assets	$	60,385		$	65,633		$	52,854		$	56,221
Liabilities and stockholders’ equity
Current liabilities
Accounts payable		90			396			287			169
Payroll related accruals		741			344			478			816
Accrued expenses and other liabilities		853			888			883			961
Income tax payable		2			2			1			2
Term note payable - related party		500			2,500			—			500
Lease liabilities, current		227			81			239			234
Total current liabilities		2,413			4,211			1,888			2,682
Lease liabilities, net of current portion		421			215			241			303
Total liabilities		2,834			4,426			2,129			2,985
Commitments and contingencies (Note 13)
Stockholders’ equity
Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at December 31, 2021 and June 30, 2021		—			—
Common stock, $0.001 par value, 250,000,000 and 50,000,000 shares authorized at December 31, 2021 and June 30, 2021, respectively; 49,514,467 and 49,450,558 shares issued and outstanding at December 31, 2021 and June 30, 2021, respectively		190,641			190,641
Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at September 30, 2022 and June 30, 2022								—			—
Common stock, $0.001 par value, 250,000,000 shares authorized at September 30, 2022 and June 30, 2022; 50,629,183 and 50,567,864 shares issued and outstanding at September 30, 2022 and June 30, 2022, respectively								190,642			190,642
Additional paid-in capital		78,769			77,971			79,892			79,505
Accumulated deficit		(211,591	)		(207,382	)		(218,242	)		(215,712	)
Accumulated other comprehensive loss		(268	)		(23	)		(1,567	)		(1,199	)
Total stockholders’ equity		57,551			61,207			50,725			53,236
Total liabilities and stockholders’ equity	$	60,385		$	65,633		$	52,854		$	56,221

Note: The balance sheet at June 30, ~~2021,~~2022, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.

See accompanying notes to unaudited condensed consolidated financial statements.

													*Three Months Ended*
	Three Months Ended December 31,						Six Months Ended December 31,						*September 30,*
	2021			2020			2021			2020			*2022*			*2021*
Revenue	$	561		$	130		$	748		$	270		$	38		$	187
Cost of revenue		441			128			616			241			32			175
Gross profit		120			2			132			29			6			12
Operating expenses:
Selling, general and administrative		1,728			803			3,154			1,729			1,642			1,426
Research and development		652			758			1,291			1,367			1,129			639
Disposal of corporate lease		—			—			—			544
Total operating expenses		2,380			1,561			4,445			3,640			2,771			2,065
Loss from operations		(2,260	)		(1,559	)		(4,313	)		(3,611	)		(2,765	)		(2,053	)
Other income and (expense), net		80			(63	)		104			(122	)		235			24
Loss from operations before income taxes		(2,180	)		(1,622	)		(4,209	)		(3,733	)		(2,530	)		(2,029	)
Income tax benefit		0			0			0			0			—			—
Net loss	$	(2,180	)	$	(1,622	)	$	(4,209	)	$	(3,733	)	$	(2,530	)	$	(2,029	)
Weighted average common shares outstanding:
Basic and diluted		47,482			15,864			47,455			11,769			48,355			47,428
Basic and diluted net loss per common share:
Net loss	$	(0.05	)	$	(0.10	)	$	(0.09	)	$	(0.32	)	$	(0.05	)	$	(0.04	)
Other comprehensive loss, net of tax:
Net loss	$	(2,180	)	$	(1,622	)	$	(4,209	)	$	(3,733	)	$	(2,530	)	$	(2,029	)
Available-for-sale securities:
Net unrealized loss		(197	)		—			(245	)		—
Net unrealized losses, net of zero tax expense														(368	)		(48	)
Total comprehensive loss	$	(2,377	)	$	(1,622	)	$	(4,454	)	$	(3,733	)	$	(2,898	)	$	(2,077	)

See accompanying notes to unaudited condensed consolidated financial statements.

Condensed Consolidated Statement of Changes in ~~Stockholders’~~Stockholders’ Equity

Preferred Stock

Series D

Common Stock

Number of
Shares
Outstanding

Amount

Number of
Shares
Outstanding

Amount

Treasury
Stock
Amount

Additional
Paid-In
Capital

Accumulated
Deficit

Accumulated
Other
Comprehensive
Loss

Total
Stockholders’
Equity

Balance at June 30, 2021

281

$
—

49,451

$
190,641

$
—

$
77,971

$
(207,382
)

$
(23
)

$
61,207

Net change in available-for-sale marketable securities

—

—

—

—

—

—

—

(48
)

(48
)
Stock-based compensation

—

—

—

—

—

359

—

—

359

Net loss

—

—

—

—

—

—

(2,029
)

—

(2,029
)
Balance at September 30, 2021

281

$
—

49,451

$
190,641

$
—

$
78,330

$
(209,411
)

$
(71
)

$
59,489

Net change in available-for-sale marketable securities

—

—

—

—

—

—

—

(197
)

(197
)
Stock-based compensation

—

—

63

—

—

439

—

—

439

Net loss

—

—

—

—

—

—

(2,180
)

—

(2,180
)
Balance at December 31, 2021

281

$
—

49,514

$
190,641

$
—

$
78,769

$
(211,591
)

$
(268
)

$
57,551

	Preferred Stock
	Series D				Common Stock
	Number of Shares Outstanding		Amount		Number of Shares Outstanding			Amount		Additional Paid-In Capital		Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
Balance at June 30, 2022		281	$	—		50,568		$	190,642	$	79,505	$	(215,712	)	$	(1,199	)	$	53,236
Net change in available-for-sale securities		—		—		—			—		—		—			(368	)		(368	)
Stock-based compensation		—		—		63			—		387		—			—			387
Cancellation of restricted stock		—		—		(2	)		—		—		—			—			—
Net loss		—		—		—			—		—		(2,530	)		—			(2,530	)
Balance at September 30, 2022		281	$	—		50,629		$	190,642	$	79,892	$	(218,242	)	$	(1,567	)	$	50,725

Preferred Stock

Series D

Common Stock

Number of
Shares
Outstanding

Amount

Number of
Shares
Outstanding

Amount

Treasury
Stock
Amount

Additional
Paid-In
Capital

Accumulated
Deficit

Accumulated
Other
Comprehensive
Loss

Total
Stockholders’
Equity

Balance at June 30, 2020

281

$
—

7,850

$
190,599

$
(4,129
)

$
13,934

$
(199,779
)

$
—

$
625

Stock offering costs

—

—

—

—

—

(2
)

—

—

(2
)
Stock-based compensation

—

—

—

—

—

49

—

—

49

Restricted stock cancellation

—

—

(6
)

—

—

(5
)

—

—

(5
)
Net loss

—

—

—

—

—

—

(2,111
)

—

(2,111
)
Balance at September 30, 2020

281

$
—

7,844

$
190,599

$
(4,129
)

$
13,976

$
(201,890
)

$
—

$
(1,444
)
Issuance of stock, net of offering costs

—

—

10,714

11

—

21,819

—

—

21,830

Stock-based compensation

—

—

—

—

—

47

—

—

47

Restricted stock cancellation

—

—

(17
)

—

—

(1
)

—

—

(1
)
Net loss

—

—

—

—

—

—

(1,622
)

—

(1,622
)
Balance at December 31, 2020

281

$
—

18,541

$
190,610

$
(4,129
)

$
35,841

$
(203,512
)

$
—

$
18,810

	Preferred Stock
	Series D				Common Stock
	Number of Shares Outstanding		Amount		Number of Shares Outstanding		Amount		Additional Paid-In Capital		Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
Balance at June 30, 2021		281	$	—		49,451	$	190,641	$	77,971	$	(207,382	)	$	(23	)	$	61,207
Net change in available-for-sale securities		—		—		—		—		—		—			(48	)		(48	)
Stock-based compensation		—		—		—		—		359		—			—			359
Net loss		—		—		—		—		—		(2,029	)		—			(2,029	)
Balance at September 30, 2021		281	$	—		49,451	$	190,641	$	78,330	$	(209,411	)	$	(71	)	$	59,489

See accompanying notes to unaudited condensed consolidated financial statements.

							*Three Months Ended*
	Six Months Ended December 31,						*September 30,*
	2021			2020			*2022*			*2021*
Cash flows from operating activities:
Net loss	$	(4,209	)	$	(3,733	)	$	(2,530	)	$	(2,029	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation, net of forfeitures		798			90
Stock-based compensation								387			359
Depreciation and amortization		94			141			89			39
Loss on disposal of assets		0			173
Changes in assets and liabilities:
Accounts receivable		(87	)		6			18			(201	)
Cost and estimated revenue in excess of billings								2			—
Inventory, net		86			88			52			(195	)
Income tax receivable		0			429
Accounts payable		(306	)		(11	)		118			(282	)
Income tax payable								(1	)		—
Other assets and liabilities		140			325			(576	)		123
Net cash used in operating activities		(3,484	)		(2,492	)		(2,441	)		(2,186	)
Cash flows from investing activities:
Purchase of investments								(4,855	)		—
Purchases of property and equipment		(264	)		(16	)		(346	)		(97	)
Net cash used in investing activities		(264	)		(16	)		(5,201	)		(97	)
Cash flows from financing activities:
Repayment of related party debt		(2,000	)		0			(500	)		(2,000	)
Payments on lease financing		(18	)		(6	)
Proceeds from issuance of stock, net of offering issuance costs		0			21,828
Net cash (used in) provided by financing activities		(2,018	)		21,822
Repayments on lease financing								(38	)		(3	)
Net cash used in financing activities								(538	)		(2,003	)
Net change in cash and cash equivalents		(5,766	)		19,314			(8,180	)		(4,286	)
Cash and cash equivalents at beginning of period		35,936			3,349			26,453			35,936
Cash and cash equivalents at end of period	$	30,170		$	22,663		$	18,273		$	31,650

Reconciliation of cash and cash equivalents and restricted cash at end of period:
Cash and cash equivalents	$	30,170		$	22,121
Restricted cash		0			542
Total	$	30,170		$	22,663

Supplemental disclosures of cash flow information:
Cash paid for interest	$	3		$	0		$	59		$	502
Income taxes paid	$	0		$	0		$	1		$	—
Acquisition of equipment through financing lease	$	394		$	—

See accompanying notes to unaudited condensed consolidated financial statements.

Description of the Company – Astrotech Corporation (Nasdaq: ASTC) (“Astrotech,” the “Company,” “we,” “us,” or “our”), a Delaware corporation organized in 1984, is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology.

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three ~~and six~~ months ended ~~December 31, 2021~~September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, ~~2022. These~~2023.These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form ~~10-K~~10-K for the year ended June 30, ~~2021.~~2022. Certain prior year amounts have been reclassified to conform to the current year ~~presentation.~~presentation and have had no impact on net income or stockholders' equity.

Accounting Pronouncements – In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ~~2021-10,~~2021-10, “Government Assistance (Topic ~~832)~~832)” (“ASU ~~2021-10”~~2021-10”), which enhances disclosure of transactions with governments that are accounted for by applying a grant or contribution model. The new pronouncement requires entities to provide information about the nature of the transaction, terms and conditions associated with the transaction, and financial statement line items affected by the transaction. ASU ~~2021-10~~2021-10 is effective for fiscal years beginning after December 15, 2021. The Company does not expect the adoption of ASU ~~2021-10~~2021-10 to have a material impact on its financial statements.

Astrotech Technologies, Inc. (“ATI”) owns and licenses the Astrotech Mass Spectrometer Technology™ (the “AMS Technology”), the platform mass spectrometry technology originally developed by 1^st Detect Corporation (“(“1^st Detect”). The AMS Technology has been designed to be inexpensive, small, and easy to use. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 2422 patents granted with 2one additional ~~patents~~patent in process along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to 3three wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1^st Detect for use in the security and detection market, to AgLAB Inc. (“AgLAB”) for use in the agriculture market, and to BreathTech Corporation (“BreathTech”) for use in breath ~~analysis.~~analysis applications.

1^st Detect, a licensee of ATI for the security and detection market, has developed the TRACER 1000™, the world’s first mass spectrometry (“MS”) based explosives trace detector (“ETD”) certified by the European Civil Aviation Conference (“ECAC”), designed to replace the ETDs used at airports, cargo and other secured facilities, and borders worldwide. The Company believes that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). The Company further believes that some IMS-based ETDs ~~are fraught~~have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those ~~several~~few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument’s performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000’s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.

In order to sell the TRACER 1000 to airport and cargo security customers in the European Union and certain other countries, we obtained ECAC ~~certification~~certification. The Company is ~~required. We are~~ currently selling the TRACER 1000 to customers who accept ECAC certification. As of September 30, 2022, the Company has deployed the TRACER 1000 in approximately 20 locations in 11 countries throughout Europe and Asia.

In the United States, the Company is working with the U.S. Transportation Security Administration (“TSA”) towards air cargo certification. On March 27, 2018, the Company announced that the TRACER 1000 was accepted into TSA’s Air Cargo Screening Technology Qualification Test (“ACSQT”) and, on April 4, 2018, the Company announced that the TRACER 1000 ~~was beginning~~ entered into testing with the TSA for passenger screening at airports. On November 14, 2019, the Company announced that the TRACER 1000 had been selected by the TSA’s Innovation Task Force to conduct live checkpoint screening at Miami International Airport. With similar protocols as ECAC testing, the Company has received valuable feedback from all programs. Following ECAC certification and the ~~Company's~~Company’s early traction within the cargo market, testing for cargo security continued with the TSA. With the ~~COVID-19~~COVID-19 pandemic, all testing within the TSA was put on hold; however, ~~the Company~~cargo testing resumed ~~cargo~~

~~testing~~ during the summer of 2020, and the Company subsequently announced on September 9, 2020 that the TRACER 1000 passed the non-detection testing portion of the TSA’s ACSQT. Due to ~~continued~~ delays caused by ~~COVID-19,~~COVID-19, TSA cargo detection testing is ongoing, but ~~proceeding~~has proceeded much more slowly than originally anticipated. As a result, efforts are primarily focused on ~~the Company’s~~our other opportunities. TSA cargo detection testing is the final step to be listed on the Air Cargo Screening Technology List ~~(“ACSTL”)~~ as an “approved” device. If approved, the TRACER 1000 will be approved for cargo sales in the United States.

~~On August 25, 2021, 1~~^st Detect announced that it secured an important landmark purchase order for the TRACER 1000, representing the first units to be deployed at an airport security checkpoint. These systems were delivered to the customer during the second quarter of fiscal year 2022.

AgLAB, an exclusive licensee of ATI for the agriculture market, has developed the ~~AgLAB-1000™~~AgLAB-1000™ series of mass spectrometers for use in the hemp and cannabis ~~market~~markets with initial focus on optimizing yields in the extraction and distillation ~~process.~~processes. The AgLAB product line is a derivative of the Company’s core AMS Technology. ~~The AMS Technology provides~~We believe hemp and cannabis distillers can gain significant improvement on their processing yields by utilizing the AgLAB-1000-D2™ system with their existing short path-molecular distillation systems. As part of our growth plan, we also plan to launch a ~~significant competitive advantage due~~family of “process control” instruments, methods, and solutions that we believe could be valuable additions to ~~its small size, rugged design, quick analysis,~~many nutraceutical extraction and ~~ease of use.~~distillation laboratories.

During the first quarter of fiscal year 2023, we began our first production run of the AgLAB-1000-D2 and sales efforts are currently underway.

BreathTech, an exclusive licensee of ATI for use in breath analysis applications, is developing the ~~BreathTest-1000~~™BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have ~~an infection, including COVID-19~~a bacterial or ~~pneumonia. While vaccines have been deployed to prevent the transmission of COVID-19, only a fraction of the world has been vaccinated and~~viral infection. The Company believes that new ~~variants continue to pose a significant and evolving threat. New~~ tools to aid in the battle against ~~COVID-19~~COVID-19 and other diseases remain of the utmost importance to help ~~defeat the disease,~~more quickly identify that an infection may be present, and BreathTech, in conjunction with Cleveland Clinic, ~~are~~is developing a quick and easy to use device to help ~~aid in preventing~~determine the ~~further spread~~presence of infections.

In June 2022, the ~~disease.~~Company expanded its existing study that initially focused on COVID-19 with Cleveland Clinic to use the BreathTest-1000 to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus (“RSV”), carriage of Staphylococcus aureus, and Clostridioides difficile (“C. diff”) infections.

Development of the ~~BreathTest-1000~~BreathTest-1000 follows the Company’s results in pre-clinical trials for the ~~BreathDetect-1000™~~BreathDetect-1000™, a rapid self-serve breathalyzer that was designed to detect bacterial infections in the respiratory tract, including pneumonia. The pre-clinical trials were conducted in collaboration with UT Health San Antonio in 2017.

The following tables summarize gains and losses related to the Company’s investments as of ~~December 31, 2021~~September 30, 2022 and June 30, ~~2021:~~2022:

December 31, 2021

Available-for-Sale

Adjusted

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Mutual Funds - Corporate & Government Debt

$
19,998

$
0

$
(179
)

$
19,819

ETFs - Corporate & Government Debt

7,376

0

(89
)

7,287

Total

$
27,374

$
0

$
(268
)

$
27,106

June 30, 2021

Available-for-Sale

Adjusted

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Mutual Funds - Corporate & Government Debt

$
19,998

$
0

$
(13
)

$
19,985

ETFs - Corporate & Government Debt

7,376

0

(10
)

7,366

Total

$
27,374

$
0

$
(23
)

$
27,351

We have certain financial instruments on our condensed consolidated balance sheet related to interest-bearing time deposits. Time deposits with maturities of less than 90 days from the purchase date are included in “Cash and Cash Equivalents.” Time deposits with maturities from 91-360 days are included in “Short-term investments.” Time deposits with maturities of more than 360 days, if any, are included in “Long-term investments.” As of September 30, 2022 and June 30, 2022, the Company had no long-term investments. For more information about the fair value of the Company’s financial instruments, see footnote 8.

~~(3)~~The following table presents the carrying amounts of certain financial instruments as of September 30, 2022 and June 30, 2022:

On April 27, 2021, Astrotech entered into a new lease for a research and development facility of approximately 5,960 square feet in Austin, Texas that includes a laboratory, a small production shop, and offices for staff, although many of the Company’s employees continue to work remotely. The lease commenced on June 1, 2021 and has a lease term of 36 months.

On August 3, 2020, the Company terminated its office lease of 5,219 square feet in Austin, Texas that housed executive management, finance and accounting, sales, and marketing and communications. The lease began in November 2016 and was originally set to expire in ~~December 2023~~. Upon lease termination, the Company recognized a decrease in the related operating right-of-use (“ROU”) asset and operating lease liability of approximately $539 thousand and $506 thousand, respectively.

Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Significant

judgement is required when determining the Company’s incremental borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Upon the adoption of Topic 842, the Company’s accounting for financing leases, previously referred to as capital leases, remains substantially unchanged from prior guidance.

The balance sheet presentation of the Company’s operating and finance leases is as follows:

(In thousands)
For the Year Ended June 30,	Operating Leases		Financing Leases		Total		*Operating Leases*		*Financing Leases*		*Total*
2022	$	52	$	77	$	129
2023		103		154		257	$	78	$	116	$	194
2024		93		154		247		93		154		247
2025		—		67		67		—		67		67
2026		—		—		—		—		—		—
2027								—		—		—
Thereafter		—		—		—		—		—		—
Total lease obligations		248		452		700		171		337		508
Less: imputed interest		18		34		52		9		19		28
Present value of net minimum lease obligations		230		418		648		162		318		480
Less: lease liabilities - current		92		135		227		98		141		239
Lease liabilities - non-current	$	138	$	283	$	421	$	64	$	177	$	241

Other information as of ~~December 31, 2021~~September 30, 2022 is as follows:

Cash payments for operating leases for the three months ended ~~December 31, 2021~~September 30, 2022 and ~~2020~~2021 totaled ~~$25~~$26 thousand and ~~$53 thousand, respectively. Cash payments for operating leases for the six months ended December 31, 2021 and 2020 totaled $35 thousand and $123 thousand, respectively.~~

~~Cash payments for financing leases for the three months ended December 31, 2021 and 2020 totaled $15 thousand and $3~~$10 thousand, respectively. Cash payments for financing leases for the ~~six~~three months ended ~~December 31, 2021~~September 30, 2022 and ~~2020~~2021 totaled ~~$18~~$38 thousand and $6$3 thousand, respectively.

Amortization of ROU assets for the three months ended September 30, 2022 and 2021 totaled $22 thousand and $21 thousand, respectively.

As of ~~December 31, 2021~~September 30, 2022 and June 30, ~~2021,~~2022, property and equipment, net consisted of the following:

Depreciation and amortization expense of property and equipment for the three months ended ~~December 31, 2021~~September 30, 2022 and ~~2020~~2021 was ~~$34~~$67 thousand and ~~$15~~$17 thousand, respectively. ~~Depreciation and amortization expense of property and equipment for the six months ended December 31, 2021 and 2020 was $51 thousand and $37 thousand, respectively.~~

On August 3, 2020, the Company terminated its corporate office lease in Austin, Texas and wrote-off the remaining net book value of the related leasehold improvement assets in the amount of $229 thousand.

The Company has issued 280,898 shares of Series D convertible preferred stock (“Series D Preferred Shares”), all of which are issued and outstanding. Series D Preferred Shares are convertible to common stock on a ~~one-to-one~~one-to-one basis. Series D Preferred Shares are not callable by the Company. The holder of the preferred stock is entitled to receive, and we shall pay, dividends on shares equal to and in the same form as dividends actually paid on shares of common stock when, and if, such dividends are paid on shares of common stock. ~~NaN~~No other dividends are paid on the preferred shares. Preferred shares have no voting rights. Upon liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary, the preferred shares have preference over common stock. The holder of Series D Preferred Shares has the option to convert said shares to common stock at the holder’s discretion.

A summary of the common stock warrant activity for the ~~six~~three months ended ~~December 31, 2021~~September 30, 2022 is presented below:

The Company has made an immaterial error correction to the table above to reflect the correct weighted average exercise price and weighted average remaining contractual term reported as of June 30, 2021. Management evaluated the materiality of the error, both quantitatively and qualitatively, and concluded that it was not material to the financial statements of any period presented.

The following represents a summary of the warrants outstanding at each of the dates identified:

					Number of Shares Underlying Warrants (In thousands)									*Number of Shares Underlying Warrants (In thousands)*
Issue Date	Classification	Exercise Price		Expiration Date	December 31, 2021		June 30, 2021			*Classification*	*Exercise Price*		*Expiration Date*	*September 30, 2022*		*June 30, 2022*
March 26, 2020	Equity	$	6.25	March 25, 2025		25		25		Equity	$	6.25	March 25, 2025		25		25
March 30, 2020	Equity	$	4.69	March 27, 2025		61		61		Equity	$	4.69	March 27, 2025		61		61
October 23, 2020	Equity	$	2.88	October 21, 2025		470		470		Equity	$	2.88	October 21, 2025		470		470
October 28, 2020	Equity	$	2.69	October 28, 2025		173		173		Equity	$	2.69	October 28, 2025		173		173
February 16, 2021	Equity	$	4.06	February 11, 2026		171		171		Equity	$	4.06	February 11, 2026		171		171
April 12, 2021	Equity	$	1.88	April 7, 2026		1,493		1,493		Equity	$	1.88	April 7, 2026		1,493		1,493
Total Outstanding						2,393		2,393	*Total Outstanding*						2,393		2,393

On December 21, 2021, the Company received a deficiency letter from ~~the~~ Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) notifying the Company of its failure to maintain compliance with the $1.00 per share of common stock minimum closing bid price requirement over the preceding 30 consecutive business days as required by Marketplace Rule 5550(a)(2). The letter statedindicating that, ~~the Company has 180 calendar days, or until June 20, 2022, to regain compliance. If at any time during this 180-day period~~based upon the closing bid price of the Company’s common stock isover the preceding 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share (the “Bid Price Requirement”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter indicated that the Company had a period of 180 calendar days, or until June 20, 2022 (the “First Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A) by having the Company’s common stock meet a closing bid price of at least $1.00 ~~per share~~ for a minimum of ten consecutive business days during the ~~Company’s compliance will be regained.~~First Compliance Period.

The Company determined that it would not be in compliance with the minimum Bid Price Requirement by June 20, 2022. As a result, the Company notified Nasdaq and applied for an extension of the compliance period, as permitted under the original notification. In the ~~event~~application, the Company ~~does not regain compliance in~~indicated that ~~period,~~ it ~~may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet~~met the continued listing requirement for market value of ~~publicly held~~publicly-held shares and all other initial listing standards for ~~The NASDAQ~~the Nasdaq Capital Market, with the exception of the minimum closing bid price ~~requirement. The Company will also need to provide~~requirement, and provided written notice of its intention to cure the deficiency during the second compliance ~~period. However,~~period of an additional 180 days by effecting a reverse stock split, if ~~it appears to~~ necessary. On June 27, 2022, the ~~NASDAQ staff~~Company received notification from Nasdaq that the date to achieve compliance had been extended an additional 180 days until December 19, 2022 (the “Second Compliance Period”). The Company ~~will neither be able nor otherwise eligible~~plans to ~~cure~~carefully assess potential actions to regain compliance during the ~~deficiency, it may be subject to delisting by NASDAQ.~~Second Compliance Period.

~~The Company has not yet determined what action, if any, it will take in response to this letter, although the Company intends to monitor~~To regain compliance, the closing bid price of ~~its~~the Company’s common stock ~~between now and June~~must be at least $1.00 per share for a minimum of ten consecutive business days during the Second Compliance Period. If the Company fails to regain compliance on or prior to December 19, 2022, ~~and to consider available options if its common~~the Company’s stock ~~does not trade at a level likely to result in~~will be delisted by Nasdaq, unless the Company ~~regaining compliance with~~timely appeals for a hearing before a Nasdaq Hearings Panel. The ~~NASDAQ Capital Market minimum closing bid price requirement.~~request for a hearing will stay any suspension or delisting action pending the issuance of the decision of the Nasdaq Hearings Panel following the hearing and the expiration of any additional extension granted by the Nasdaq Hearings Panel.

Basic net loss per share is computed on the basis of the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed based on the weighted average number of common shares outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method and the if-converted method. Potentially dilutive common shares include outstanding stock options and share-based awards.

The following table reconciles the numerators and denominators used in the computations of both basic and diluted net loss per share:

All unvested restricted stock awards for the ~~six~~three months ended ~~December 31, 2021~~September 30, 2022 are not included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive. Options to purchase ~~152,532~~1,111,532 shares of common stock at exercise prices ranging from ~~$1.85~~$0.44 to ~~$6.00~~$5.85 per share outstanding as of ~~December 31, 2021~~September 30, 2022 were not included in diluted net loss per share, as the impact to net loss per share would be anti-dilutive.

Astrotech recognizes revenue employing the generally accepted revenue recognition methodologies described under the provisions of Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers” (“Topic 606”), which was adopted by the Company in fiscal year 2019. The methodology used is based on contract type and how products and services are provided. The guidelines of Topic 606 establish a ~~five-step~~five-step process to govern the recognition and reporting of revenue

from contracts with customers. The five steps are: (i) identify the contract with a customer, (ii) identify the performance obligations within the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations within the contract, and (v) recognize revenue when or as the performance obligations are satisfied.

An additional factor is reasonable assurance of collectability. This necessitates deferral of all or a portion of revenue recognition until collection. During the ~~six~~three months ended ~~December 31, 2021,~~September 30, 2022, the Company had 2 threerevenue sources that comprised all of its revenue. Revenue was recognized at a point in time consistent with the guidelines in Topic 606.

Contract Assets and Liabilities. The Company enters into contracts to sell products and provide services, and it recognizes contract assets and liabilities that arise from these transactions. The Company recognizes revenue and corresponding accounts receivable according to Topic 606 and, at times, recognizes revenue in advance of the time when contracts give us the right to invoice a customer. The Company may also receive consideration, per the terms of a contract, from customers prior to transferring goods to the customer. The Company records customer deposits as deferred revenue. Additionally, the Company may receive payments, most typically for service and warranty contracts, at the onset of the contract and before services have been performed. In such instances, the Company records a deferred revenue liability. The Company recognizes these contract liabilities as sales after all revenue recognition criteria are met.

Practical Expedients. In cases where the Company is responsible for shipping after the customer has obtained control of the goods, the Company has elected to treat the shipping activities as fulfillment activities rather than as a separate performance obligation. Additionally, the Company has elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than one year. The Company only gives consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than one year.

Product Sales. The The Company recognizes revenue from sales of products upon shipment or delivery when control of the product transfers to the customer, depending on the terms of each sale, and when collection is probable. In the circumstance where terms of a product sale include subjective customer acceptance criteria, revenue is deferred until the Company has achieved the acceptance criteria unless the customer acceptance criteria are perfunctory or inconsequential. TheThe Company generally offers customers payment terms of 60 days or less.

Freight. The The Company records shipping and handling fees that it charges to its customers as revenue and related costs as cost of revenue.

Multiple Performance Obligations. Certain agreements with customers include the sale of equipment involving multiple elements in cases where obligations in a contract are distinct and thus require separation into multiple performance obligations, revenue recognition guidance requires that contract consideration be allocated to each distinct performance obligation based on its relative standalone selling price. The value allocated to each performance obligation is then recognized as revenue when the revenue recognition criteria for each distinct promise or bundle of promises has been met.

The standalone selling price for each performance obligation is an amount that depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the good or service. When there is only one performance obligation associated with a contract, the entire amount of consideration is attributed to that obligation. When a contract contains multiple performance obligations, the standalone selling price is first estimated using the observable price, which is generally a list price net of applicable discount or the price used to sell the good or service in similar circumstances. In circumstances when a selling price is not directly observable, the Company will estimate the standalone selling price using information available to it including its market assessment and expected cost, plus margin.

The timetable for fulfilment of each of the distinct performance obligations can range from completion in a short amount of time and entirely within a single reporting period to completion over several reporting periods. The timing of revenue recognition for each performance obligation may be dependent upon several milestones, including physical delivery of equipment, completion of site acceptance test, and in the case of after-market consumables and service deliverables, the passage of time.

ASC Topic 820 “Fair Value Measurement” (“Topic 820”) defines fair value, establishes a market-based framework or hierarchy for measuring fair value, and expands disclosures about fair value measurements. Topic 820 is applicable whenever assets and liabilities are measured and included in the financial statements at fair value.

The fair value hierarchy established in Topic 820 prioritizes the inputs used in valuation techniques into three levels as follows:

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

The following tables present the carrying amounts, estimated fair values, and valuation input levels of certain financial instruments as of ~~December 31, 2021~~September 30, 2022 and June 30, ~~2021:~~2022:

	December 31, 2021										*September 30, 2022*
Available-for-Sale	Carrying		Fair Value Measured Using						Fair
											*Carrying*		*Fair Value Measured Using*						*Fair*
(In thousands)	Amount		Level 1		Level 2		Level 3		Value		*Amount*		*Level 1*		*Level 2*		*Level 3*		*Value*
Available-for-Sale Securities
Cash Equivalents
Time deposits: 1-90 days											$	735	$	—	$	735	$	—	$	735
Total Cash Equivalents												735		—		735		—		735
Short-Term Investments
Mutual Funds - Corporate & Government Debt	$	19,819	$	19,819	$	—	$	—	$	19,819		18,955		18,955		—		—		18,955
ETFs - Corporate & Government Debt		7,287		7,287		—		—		7,287		6,877		6,877		—		—		6,877
Total	$	27,106	$	27,106	$	—	$	—	$	27,106

	June 30, 2021
Available-for-Sale	Carrying		Fair Value Measured Using						Fair
(In thousands)	Amount		Level 1		Level 2		Level 3		Value
Mutual Funds - Corporate & Government Debt	$	19,985	$	19,985	$	—	$	—	$	19,985
ETFs - Corporate & Government Debt		7,366		7,366		—		—		7,366
Total	$	27,351	$	27,351	$	—	$	—	$	27,351
Time deposits: 91-360 days												4,843		—		4,843		—		4,843
Total Short-Term Investments												30,675		25,832		4,843		—		30,675
Total Available-for-Sale Securities											$	31,410	$	25,832	$	5,578	$	—	$	31,410

The value of available-for-sale ~~investments~~securities with Level 1 inputs is based on pricing from ~~third-party~~third-party pricing vendors, who use quoted prices in active markets for identical ~~assets (Level 1 inputs).~~assets. The fair value measurements used for time deposits are considered Level 2 and use pricing from third-party pricing vendors who use quoted prices for identical or similar securities in both active and inactive markets.

On September 5, 2019, the Company entered into a private placement transaction with Thomas B. Pickens III, the Chief Executive Officer and Chairman of the Board of Directors of the Company, for the issuance and sale of a secured promissory note to Mr. Pickens with a principal amount of $1.5 million (the ~~“2019~~“2019 Note”), and on February 13, 2020, the Company entered into a second private placement transaction with Mr. Pickens for the issuance and sale of a second secured promissory note to Mr. Pickens with a principal amount of $1.0 million (the ~~“2020~~“2020 Note” and, collectively with the 2019 Note, the “Original Notes”). Interest on the Original Notes accrued at 11% per annum. The principal amount and accrued interest on the Original Notes originally were to become due and payable on September 5, 2020; however, on August 24, 2020, the Company and Mr. Pickens agreed to extend the date of maturity of the Original Notes and payment of accrued interest to September 5, 2021 ~~(the “Original~~(the “Extended Maturity Date”). The Company had the option to prepay the principal amount and all accrued interest on the Original Notes at any time prior to the ~~Original~~Extended Maturity Date.

In connection with the issuance of the Original Notes, the Company, along with 1^st Detect Corporation and Astrotech Technologies, Inc. (the “Subsidiaries”), entered into two security agreements, dated as of September 5, 2019 and February 13, 2020 ~~(collectively,~~(collectively, the “Original Security Agreements”), with Mr. Pickens, pursuant to which the Company and the Subsidiaries granted to Mr. Pickens a security interest in all of the Company’s and the Subsidiaries’ Collateral, as such term is defined in the Original Security Agreements. In addition, the Subsidiaries jointly and severally agreed to guarantee and act as surety for the Company’s obligation to repay the Original Notes pursuant to a subsidiary guarantee.

On September 3, 2021, the Company entered into ~~(1)~~(1) the Omnibus Amendment to the Secured Promissory Notes (the “Amended Notes”) with Mr. Pickens, in connection with the Original Notes, and ~~(2)~~(2) the Omnibus Amendment to the Security Agreements (the “Amended Security Agreements”, and together with the Amended Notes, the “Amendments”) with the Subsidiaries, in connection with the Original Security Agreements. Pursuant to the Amendments, (a) the principal amount of $1.0 million and accrued interest of $172 thousand on the 2020 Note was paid in full and the 2020 Note was ~~cancelled,~~canceled, and (b) $1.0 million of the principal amount and $330 thousand of accrued interest on the 2019 Note was paid and the maturity date on the remaining balance of $500 thousand of the 2019 Note was extended to September 5, 2022 ~~(the~~(the “Amended Maturity Date”).

In addition, the Subsidiaries jointly and severally agreed to guarantee and act as surety for the Company’s obligation to repay the remaining balance on the 2019 Note pursuant to subsidiary guarantees, dated September 5, 2019 and February 13, 2020, ~~respectively,~~ as amended by the Omnibus Amendments to Subsidiary Guarantees, dated August 24, 2020 and September 3, 2021, respectively (the Omnibus Amendment to Subsidiary Guarantees dated September 3, 2021, the “Amended Subsidiary Guarantee”). The Subsidiary ~~Guaranty~~Guarantee with respect to the 2020 Note was also ~~cancelled~~canceled by the Amended Subsidiary Guarantee due to the 2020 Note being repaid in full.

~~(10)~~On September 5, 2022, the 2019 Note matured and the principal amount of $500 thousand and accrued interest of $55 thousand was paid in full and the 2019 Note was canceled. With the cancelation of the 2019 Note, the Amended Subsidiary Guarantee was terminated and the Subsidiaries' Collateral was released.

For the ~~each of the~~ three ~~and six~~ months ended ~~December 31, 2021,~~September 30, 2022, the Company had 2three customers that comprised all of the Company’s revenue. For the three months ended September 30, 2021, the Company had one customer that materially comprised all of the Company's revenue.

The Company maintains funds in bank accounts that may exceed the limit insured by the Federal Deposit Insurance Corporation of $250 thousand per depositor. The risk of loss attributable to these uninsured balances is mitigated by depositing funds in what we believe to be high credit quality financial institutions. The Company has not experienced any losses in such accounts.

The Company’s stock option activity for the ~~six~~three months ended ~~December 31, 2021~~September 30, 2022 is as follows:

The aggregate intrinsic value of options exercisable at ~~December 31, 2021~~September 30, 2022 was $0, as the fair value of the Company’s common stock is less than the exercise prices of these options. The remaining stock-based compensation expense of $1$495 thousand related to stock options will be recognized over a weighted-average period of ~~0.78~~2.58 years.

The table below details the Company’s stock options outstanding as of ~~December 31, 2021:~~September 30, 2022:

Range of exercise prices

Number
Outstanding (In thousands)

Options
Outstanding
Weighted-
Average
Remaining
Contractual
Life (Years)

Weighted-
Average
Exercise
Price

Number
Exercisable (In thousands)

Options
Exercisable
Weighted-
Average
Exercise
Price

$1.85 – 2.83

13

6.74

$
2.08

10

$
2.15

$5.00 – 5.85

88

5.36

5.55

88

5.55

$6.00 – 6.00

52

0.64

6.00

52

6.00

$1.85 – 6.00

153

3.87

$
5.41

150

$
5.49

Compensation costs recognized related to stock option awards were $46 thousand and $0 for each of the three months ended ~~December 31, 2021,~~September 30, 2022, and ~~2020 and $1 thousand for each of the six months ended December 31,~~ 2021 ~~and 2020.~~.

The Company’s restricted stock activity for the ~~six~~three months ended ~~December 31, 2021,~~September 30, 2022, is as follows:

Stock compensation expenses related to restricted stock were ~~$439~~$341 thousand and ~~$46~~$359 thousand for the three months ended ~~December 31, 2021,~~September 30, 2022, and ~~2020, respectively, and $797 thousand and $90 thousand for the six months ended December 31,~~ 2021 ~~and 2020,~~, respectively. The remaining stock-based compensation expense of ~~$3.0~~$2.3 million related to restricted stock awards granted will be recognized over a weighted-average period of ~~2.23~~2.31 years.

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of ~~December 31, 2021,~~September 30, 2022, the Company established a valuation allowance against all of its net deferred tax assets.

For the three months ended ~~December 31, 2021~~September 30, 2022 and ~~2020,~~2021, the Company incurred pre-tax losses in the amount of ~~$2.2~~$2.5 million and ~~$1.6 million, respectively. For the six months ended December 31, 2021 and 2020, the Company incurred pre-tax losses in the amount of $4.2 million and $3.7~~$2.0 million, respectively. The total effective tax rate was approximately 0% for ~~the~~ each of the three ~~and six~~ months ended ~~December 31, 2021~~September 30, 2022 and ~~2020.~~2021.

For each of the ~~six~~three months ended ~~December 31, 2021~~September 30, 2022 and ~~2020,~~2021, the Company’s effective tax rate differed from the federal statutory rate of 21%, primarily due to the valuation allowance placed against its net deferred tax assets.

The ~~Coronavirus Aid, Relief,~~Inflation Reduction Act and ~~Economic Security~~the Chips and Science Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act provided certain tax relief measures including the acceleration of the alternative minimum tax (“AMT”) credit previously paid. The CARES Act allows for the acceleration of the refundable AMT credit up to 100% of the AMT credit. In responsewere enacted in August 2022. There is no material impact to the ~~impact of the CARES Act, the~~ Company ~~received the remaining AMT credit of $429 thousand for AMT previously paid during the three months ended September 30, 2020.~~from these new tax laws.

FASB ASC 740, “Income Taxes” addresses the accounting for uncertainty in income tax recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. The Company currently has approximately ~~$300~~$400 thousand of uncertain tax positions as of ~~December 31, 2021,~~September 30, 2022, all of which are accounted as contra-deferred tax assets. The Company does 0tnot expect any significant changes to its uncertain tax positions in the coming 12 months.

Loss carryovers are generally subject to modification by tax authorities until three years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended 2001 through present for federal purposes and fiscal years ended 2006 through present for state purposes.

The Company is subject to various lawsuits and other claims in the normal course of business. In addition, from time to time, the Company receives communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which the Company operates.

The Company establishes reserves for the estimated losses on specific contingent liabilities, for regulatory and legal actions where the Company deems a loss to be probable and the amount of the loss can be reasonably estimated. In other instances, the Company is not able to make a reasonable estimate of liability because of the uncertainties related to the outcome or the amount or range of potential loss.

On April 15, 2021, a putative stockholder of the Company commenced a class action and derivative lawsuit in the Delaware Court of Chancery, Stein v. Pickens, et al., C.A. No.2021-0322-JRS (the “Stein Action”), in which it was alleged, among other things, that the Company improperly included broker non-votes in the tabulation of votes counted in favor to approve an amendment to the Company’s Certificate of Incorporation (the “2020 Certificate Amendment”) and, thus the 2020 Certificate Amendment was defective. The Company investigated those allegations and does not believe that the filing and effectiveness of the 2020 Certificate Amendment was either invalid or ineffective. Nevertheless, to resolve any uncertainty, on April 30, 2021, the Company filed a validation proceeding in the Delaware Court of Chancery, In re Astrotech Corporation, C.A. No.2021-0380-JRS, pursuant to Section 205 of the Delaware General Corporation Law. On October 6, 2021, the Delaware Court of Chancery granted the Company’s request and confirmed and validated the 2020 Certificate Amendment. Thereafter, a settlement in principle was reached with the Plaintiffs in the Stein Action and the parties to the Stein Action presently anticipate presenting the settlement for approval on December 12, 2022.

Further information regarding the Stein Action and the Section 205 Action is provided in the Schedule 14A proxy statement amendment and supplement filed by the Company with the SEC on April 29, 2021.

The Company has determined that it does not meet the criteria of ASC 280 “Segment Reporting” because the Company’s subsidiaries represent Company brands that leverage the same core technology rather than independent operating segments. Furthermore, restatement of prior results is not necessary as they would mirror the consolidated results.

The Company has taken what it believes are necessary precautions to safeguard its employees from the COVID-19 pandemic. The Company continues to follow the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. All of the Company’s employees who do not work in a lab setting are currently on a telecommunication work arrangement and have been able to successfully work remotely. The Company’s lab requires in-person staffing, and the Company has been able to continue to operate its lab. There can be no assurance, however, that key employees will not become ill or that the Company will be able to continue to operate its labs.

To date, the Company has seen delays with respect to the TSA certification process and parts of its supply chain, particularly the impact of the global semiconductor and electronics shortage, which has now resulted in product pricing inflation. In addition, although passenger demand for air travel has rebounded, the overall recovery of the airline industry and ancillary services remains highly uncertain and is dependent upon, among other things, the number of cases declining around the globe, public health impacts of new COVID-19 variants, the continued administration of vaccines to unvaccinated populations, and the duration of immunity granted by vaccines.

The Company continues to manage production, to secure alternative supplies, and to take other proactive actions. The Company believes that it will be able to pass the inflation caused by raw materials shortages and increased shipping costs to its customers by increasing the price of its instruments. If supply chain shortages become more severe or longer term in nature, the Company’s business and results of operations could be adversely impacted; however, the Company does not expect this issue to materially adversely affect its liquidity position. The long-term impact of the COVID-19 pandemic on the Company’s business may not be fully reflected until future periods.

On March 27, 2020, the CARES Act was enacted. The CARES Act, among other things, includes provisions relating to refundable payroll taxes, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The most significant relief measures which the Company qualified for are a loan pursuant to the Paycheck Protection Program for which the Company has received full forgiveness, alternative minimum tax credit refunds, employee retention credit, and payroll tax deferral. The payroll tax deferral was effective from the enactment date through December 31, 2020, and the deferred amount will be repaid in two installments. 50% of the deferred amount has been paid as of December 31, 2021, and the remainder will be due by December 31, 2022. The deferred payroll taxes are recorded within accrued liabilities on the condensed consolidated balance sheets.

The Company will continue to assess the treatment of the CARES Act to the extent additional guidance and regulations are issued, the further applicability of the CARES Act to the Company, and the potential impacts on the business.

On November 9, 2022, the Company’s Board of Directors authorized a share repurchase program that allows the Company to repurchase up to $1.0 million of the Company’s common stock beginning November 17, 2022, and continuing through and including November 17, 2023. The shares may be repurchased from time to time in open market or privately negotiated transactions or by other means in accordance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including management’s assessment of the intrinsic value of the Company’s common stock, the market price of the Company’s common stock, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal requirements, and other considerations. The exact number of shares to be repurchased by the Company is not guaranteed, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases with available working capital.

On November 11, 2022, the Company signed a lease extension agreement for the Company’s offices located in Austin, Texas, extending the term of the lease through March 2025. The Company’s total contractual base rent obligation for the ten-month extension is approximately $87 thousand.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words “may,” “will,” “plans,” “believes,” “estimates,” “expects,” “intends,” and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our 2022 Annual Report on Form 10-K, elsewhere in this Quarterly Report on Form 10-Q, or those discussed in other documents we filed with the SEC. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the SEC or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report.

Astrotech Corporation (Nasdaq: ASTC) (“Astrotech,” the “Company,” “we,” “us,” or “our”), a Delaware corporation organized in 1984, is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology.

Our efforts are focused on commercializing our platform mass spectrometry technology through our wholly-owned subsidiaries:

ATI owns and licenses the AMS Technology, the platform mass spectrometry technology originally developed by 1st Detect. Long recognized as the gold standard in chemical detection, mass spectrometry has historically been too costly, bulky, and cumbersome. In contrast, the AMS Technology has been designed to be inexpensive, small, and easy to use. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 22 granted patents and one additional patent in process along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to three wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1^st Detect for use in the security and detection market, to AgLAB for use in the agriculture market, and to BreathTech for use in breath analysis applications.

ATI has contracted with Sanmina Corporation (“Sanmina”), a leading contract manufacturer with a worldwide presence, to manufacture our mass spectrometer products. Leveraging their expertise, Sanmina has helped to improve the manufacturability and reliability of our systems.

1^st Detect, a licensee of ATI for the security and detection market, has developed the TRACER 1000™, the world’s first mass spectrometer (“MS”) based explosives trace detector (“ETD”) certified by the European Civil Aviation Conference (“ECAC”), designed to replace the ETDs used at airports, cargo and other secured facilities, and borders worldwide. We believe that some ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). We further believe that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those few explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument’s performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000’s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.

In order to sell the TRACER 1000 to airport and cargo security customers in the European Union and certain other countries, we obtained ECAC certification. We are currently selling the TRACER 1000 to customers who accept ECAC certification. As of September 30, 2022, we have deployed the TRACER 1000 in approximately 20 locations in 11 countries throughout Europe and Asia.

In the United States, we are working with the U.S. Transportation Security Administration (“TSA”) towards air cargo certification. On March 27, 2018, we announced that the TRACER 1000 was accepted into TSA’s Air Cargo Screening Technology Qualification Test (“ACSQT”) and, on April 4, 2018, we announced that the TRACER 1000 was beginning testing with the TSA for passenger screening at airports. On November 14, 2019, we announced that the TRACER 1000 had been selected by the TSA’s Innovation Task Force to conduct live checkpoint screening at Miami International Airport. With similar protocols as ECAC testing, we have received valuable feedback from all programs. Following ECAC certification and our early traction within the cargo market, testing for cargo security continued with the TSA. With the onset of the COVID-19 pandemic, all testing within the TSA was put on hold; however, we resumed cargo testing during the summer of 2020, and we subsequently announced on September 9, 2020, that the TRACER 1000 passed the non-detection testing portion of the TSA’s ACSQT. Due to delays caused by COVID-19, TSA cargo detection testing is ongoing, but has proceeded much more slowly than originally anticipated. As a result, efforts are primarily focused on our other opportunities. TSA cargo detection testing is the final step to be listed on the Air Cargo Screening Technology List as an “approved” device. If approved, the TRACER 1000 will be approved for cargo sales in the United States.

AgLAB, an exclusive licensee of ATI for the agriculture market, has developed the AgLAB-1000™ series of mass spectrometers for use in the hemp and cannabis markets with initial focus on optimizing yields in the extraction and distillation processes. The AgLAB product line is a derivative of our core AMS Technology. The AMS Technology provides a significant competitive advantage due to its small size, rugged design, quick analysis, and ease of use. AgLAB has continued to conduct field trials to demonstrate that the AgLAB-1000-D2™ can be used in the distillation process to significantly improve the processing yields of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) oil during distillation. As part of our growth plan, we also plan to launch a family of “process control” instruments, methods, and solutions that we believe could be valuable additions to many nutraceutical extraction and distillation laboratories.

During the first quarter of fiscal year 2023, we began our first production run of the AgLAB-1000-D2 and sales efforts are currently underway.

BreathTech, an exclusive licensee of ATI for use in breath analysis applications, is developing the BreathTest-1000™, a breath analysis tool to screen for VOC metabolites found in a person’s breath that could indicate they may have a bacterial or viral infection. We believe that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present, and BreathTech, in conjunction with Cleveland Clinic, is developing a quick and easy to use device to help determine the presence of infections.

In June 2022, we expanded our existing study that initially focused on COVID-19 with Cleveland Clinic to use the BreathTest-1000 to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus (“RSV”), carriage of Staphylococcus aureus, and Clostridioides difficile (“C. diff”) infections.

BreathTech recently contracted with a clinical research firm to assist in procuring breath samples collected from patients. These samples are being used to further develop the library of the BreathTest-1000. Preliminary results have shown that the BreathTest-1000 can discriminate between background breath and the disease VOCs.

Development of the BreathTest-1000 follows our results in pre-clinical trials for the BreathDetect-1000™, a rapid self-serve breathalyzer that was designed to detect bacterial infections in the respiratory tract, including pneumonia. The pre-clinical trials were conducted in collaboration with UT Health San Antonio in 2017.

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. To date, we have seen delays with respect to the TSA certification process and parts of our supply chain, particularly the impact of the global semiconductor and electronics shortage, which has now resulted in product pricing inflation. In addition, although passenger demand for air travel has rebounded, the overall recovery of the airline industry and ancillary services remains highly uncertain and is dependent upon, among other things, the number of cases declining around the globe, public health impacts of new COVID-19 variants, the continued administration of vaccines to unvaccinated populations, and the duration of immunity granted by vaccines.

We continue to manage production, to secure alternative supplies where available, and to take other proactive actions. We believe that we will be able to pass the inflation caused by raw materials shortages and increased shipping costs to our customers by increasing the price of our instruments. If supply chain shortages become more severe or longer term in nature, our business and results of operations could be adversely impacted; however, we do not expect this issue to materially adversely affect our liquidity position. The long-term impact of the COVID-19 pandemic on our business may not be fully reflected until future periods.

We continue to evaluate the current and potential impact of the pandemic on our business, results of operations, and consolidated financial statements. We also continue to actively monitor developments and business conditions, including those that may be related to additional COVID-19 variants and other diseases, that may cause us to take further actions that alter business operations as may be required by applicable authorities or that we determine are in the best interests of our employees, customers, suppliers, and stockholders.

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). The preparation of these financial statements requires us to make estimates and judgments that directly affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. A critical accounting estimate is one that involves a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management continuously evaluates its critical accounting policies and estimates, including those used in evaluating the recoverability of long-lived assets, recognition of revenue, valuation of inventory, and the recognition and measurement of loss contingencies, if any. Actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates as set forth in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended June 30, 2022.

Three months ended September 30, 2022, compared to three months ended September 30, 2021:

Selected consolidated financial data for the quarters ended September 30, 2022, and 2021 is as follows:

Revenue – Total revenue decreased by $149 thousand during the first quarter of fiscal 2023, compared to the first quarter of fiscal 2022. In the first quarter of fiscal 2023, all revenue was comprised of consumables and maintenance services for the TRACER 1000 and a short-term rental of a TRACER 1000 system. In the first quarter of fiscal 2022, all revenue was related to the sales of our TRACER 1000 to DHL (Deutsche Post AG). The decrease in revenue is primarily the result of Astrotech shifting its sales efforts from the volatile ETD market and concentrating on commercializing, marketing, and selling the AgLAB-1000-D2. We believe that the AgLAB market should provide for a more profitable opportunity versus the commoditized ETD market.

Cost of Revenue – Gross profit is comprised of revenue less cost of revenue. In the first quarter of fiscal 2023 and 2022, cost of revenue was comprised of labor, materials, shipping, warranty reserve and overhead allocation related to the sale of TRACER 1000 units. Cost of revenue decreased $143 thousand during the first quarter of fiscal 2023, compared to the first quarter of fiscal 2022 due to the decrease in revenue as described above. Gross margin increased by 10% in the first quarter of fiscal 2023, compared to the first quarter of fiscal 2022 due to our revenue being comprised of recurring services and materials as opposed to mainly system sales.

Operating Expenses – Operating expenses increased $706 thousand, or 34.2%, during the first quarter of fiscal 2023, compared to the first quarter of fiscal 2022. Significant changes to operating expenses include the following:

Income Taxes –Income tax benefit did not change during the first quarter of fiscal 2023, compared to the first quarter of fiscal 2022. The realization of tax benefits depends on the existence of future taxable income. Pursuant to Accounting Standards Codification (“ASC”) 740 “Income Taxes”, a valuation allowance has been established on all of our deferred tax assets.

As of September 30, 2022, we held cash and cash equivalents of $18.2 million, and our working capital was approximately $49.4 million. As of June 30, 2022, we had cash and cash equivalents of $26.4 million, and our working capital was approximately $52.3 million. Cash and cash equivalents decreased $8.2 million as of September 30, 2022, compared to June 30, 2022, due to the purchases of short-term time deposit investments as well as continuing operating expenses.

Cash used in operating activities increased $255 thousand for the three months ended September 30, 2022, compared to thethree months ended September 30, 2021, due to a decrease in payroll-related accruals and an increase in operating expenses, partially offset by an increase of accounts payable and a decrease in accounts receivable.

On November 9, 2022, the Company’s Board of Directors authorized a share repurchase program that allows the Company to repurchase up to $1.0 million of the Company’s common stock beginning November 17, 2022, and continuing through and including November 17, 2023. The shares may be repurchased from time to time in open market or privately negotiated transactions or by other means in accordance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including management’s assessment of the intrinsic value of the Company’s common stock, the market price of the Company’s common stock, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal requirements, and other considerations. The exact number of shares to be repurchased by the Company is not guaranteed, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases with available working capital.

Cash used in investing activities increased $5.1 million for the three months ended September 30, 2022, compared to thethree months ended September 30, 2021, due to the purchases of short-term time deposit investments.

Cash used in financing activities decreased $1.5 million for the three months ended September 30, 2022, compared to the three months ended September 30, 2021, due to a larger repayment of related party debt in the prior year. We did not have any material off-balance sheet arrangements as of September 30, 2022.

During the fiscal year 2021, we successfully completed several public offerings of our common stock, raising net proceeds of approximately $67.6 million which will be used to satisfy our short-term and long-term capital needs. There have been no material updates to our expectations for our short- and long-term liquidity and operating capital requirements since our Annual Report on Form 10-K for the year ended June 30, 2022.

Our effective tax rate is 0% for income tax for the three months ended September 30, 2022, and we expect that our effective tax rate for the full fiscal year 2023 year will be 0%. Based on the weight of available evidence, including net cumulative losses and expected future losses, we have determined that it is more likely than not that our U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets.

In general, if we experience a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change net operating loss (“NOL”) carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code. Generally, U.S. state laws have laws similar to Internal Revenue Code Section 382. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforward before utilization.

We file U.S. federal and state income tax returns. We are not currently subject to any income tax examinations. Dating back to June 2002, we have net operating loss carryovers, which generally allows all tax years to remain open to income tax examinations for all years for which there are loss carryforwards.

We recognize the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. We currently have approximately $400 thousand of uncertain tax positions as of September 30, 2022, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.

There is $0 provision for income taxes during each of the three months ended September 30, 2022 and 2021.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management was required to apply its judgment in evaluating and implementing possible controls and procedures. Management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2022 at the reasonable assurance level.

There have been no changes in our internal controls over financial reporting that occurred during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

On April 15, 2021, a putative stockholder of the Company commenced a class action and derivative lawsuit in the Delaware Court of Chancery, Stein v. Pickens, et al., C.A. No. 2021-0322-JRS (the “Stein Action”), in which it was alleged, among other things, that the Company improperly included broker non-votes in the tabulation of votes counted in favor to approve an amendment to the Company’s Certificate of Incorporation (the “2020 Certificate Amendment”) and, thus the 2020 Certificate Amendment was defective. The Company investigated those allegations and does not believe that the filing and effectiveness of the 2020 Certificate Amendment was either invalid or ineffective. Nevertheless, to resolve any uncertainty, on April 30, 2021, the Company filed a validation proceeding in the Delaware Court of Chancery, In re Astrotech Corporation, C.A. No. 2021-0380-JRS, pursuant to Section 205 of the Delaware General Corporation Law. On October 6, 2021, the Delaware Court of Chancery granted the Company’s request and confirmed and validated the 2020 Certificate Amendment. Thereafter, a settlement in principle was reached with the Plaintiffs in the Stein Action and the parties to the Stein Action presently anticipate presenting the settlement for approval ~~in the first half of~~on December 12, 2022.

Further information regarding the Stein Action and the Section 205 Action is provided in the Schedule 14A proxy statement amendment and supplement filed by the Company with the SEC on April 29, 2021.

The Company has determined that it does not meet the criteria of ASC 280 “Segment Reporting” because the Company’s subsidiaries represent Company brands that leverage the same core technology rather than independent operating segments. Furthermore, restatement of prior results is not necessary as they would mirror the consolidated results.

The Company has taken what it believes are necessary precautions to safeguard its employees from the COVID-19 pandemic. The Company continues to follow the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. All of the Company’s employees who do not work in a lab setting are currently on a telecommunication work arrangement and have been able to successfully work remotely. The Company’s lab requires in-person staffing, and the Company has been able to continue to operate its lab. There can be no assurance, however, that key employees will not become ill or that the Company will be able to continue to operate its labs.

~~The Company~~ continues to manage production, to secure alternative supplies, and to take other proactive actions. The Company believes that it will be able to pass the inflation caused by raw materials shortages and increased shipping costs to its customers by increasing the price of its instruments. If supply chain shortages become more severe or longer term in nature, ~~the Company’s~~ ~~business and results of operations could be adversely impacted; however,~~ ~~the Company~~ ~~does not expect this issue to materially adversely affect its liquidity position. The long-term impact of the COVID-19 pandemic on~~ ~~the Company’s~~ ~~business may not be fully reflected until future periods.~~

The Company continues to evaluate the current and potential impact of the pandemic on its business, results of operations, and consolidated financial statements. The Company also continues to actively monitor developments and business conditions that may cause it to take further actions that alter business operations as may be required by applicable authorities or that it determines are in the best interests of its employees, customers, suppliers, and stockholders.

On March 27, 2020, the CARES Act was enacted. The CARES Act, among other things, includes provisions relating to refundable payroll taxes, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. The most significant relief measures which the Company qualified for are a loan pursuant to the Paycheck Protection Program for which the Company has received full forgiveness, alternative minimum tax credit refunds, employee retention credit, and payroll tax deferral. ~~The payroll tax deferral was effective from the enactment date through December 31, 2020, and the deferred amount will be repaid in~~ ~~two~~ ~~installments.~~ 50% of the deferred amount has been paid as of December 31, 2021, and the remainder will be due by December 31, 2022. The deferred payroll taxes are recorded within accrued liabilities on the condensed consolidated balance sheets.

The Company has analyzed its operations subsequent to December 31, 2021 to the date these unaudited condensed consolidated financial statements were issued and has determined that it does not have any material subsequent events to disclose in these unaudited condensed consolidated financial statements.

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate; therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in our 2021 Annual Report on Form 10-K, elsewhere in this Quarterly Report on Form 10-Q, or in the documents incorporated by reference herein. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events, or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the Securities and Exchange Commission (“SEC”) or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.

~~ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~

~~The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report.~~

~~Our efforts are focused on commercializing our platform mass spectrometry technology through our wholly-owned subsidiaries:~~

ATI owns and licenses the AMS Technology, the platform mass spectrometry technology originally developed by 1st Detect. Long recognized as the gold standard in chemical detection, mass spectrometry has historically been too costly, bulky, and cumbersome. In contrast, the AMS Technology has been designed to be inexpensive, small, and easy to use. Unlike other technologies, the AMS Technology works under ultra-high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The intellectual property includes 24 granted patents and two additional patents in process along with extensive trade secrets. With a number of diverse market opportunities for the core technology, ATI is structured to license the intellectual property for different fields of use. ATI currently licenses the AMS Technology to three wholly-owned subsidiaries of Astrotech on an exclusive basis, including to 1^st ~~Detect for use in the security and detection market, to AgLAB for use in the agriculture market, and to BreathTech for use in breath analysis.~~

ATI has contracted with Sanmina Corporation (“Sanmina”), a leading contract manufacturer with a worldwide presence. Sanmina has already helped to reduce the cost of the TRACER 1000™, and we have leveraged their expertise to improve manufacturability and reliability of our systems.

1^st Detect, a licensee of ATI for the security and detection market, has developed the TRACER 1000, the world’s first mass spectrometry (“MS”) based explosives trace detector (“ETD”) certified by the European Civil Aviation Conference (“ECAC”), designed to replace the ETDs used at airports, cargo and other secured facilities, and borders worldwide. We believe that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (“IMS”). We believe that IMS-based ETDs are fraught with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources. In addition, there are hundreds of different types of explosives, but IMS-based ETDs have a very limited threat detection library reserved only for those several explosives of largest concern. Adding additional compounds to the detection library of an IMS-based ETD fundamentally reduces the instrument’s performance, further increasing the likelihood of false alarms. In contrast, adding additional compounds to the TRACER 1000’s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.

In order to sell the TRACER 1000 to airport and cargo security customers in the European Union and certain other countries, ECAC certification is required. We are currently selling the TRACER 1000 to customers who accept ECAC certification. We have deployed or received orders for the TRACER 1000 in approximately twenty locations in thirteen countries throughout Europe and Asia.

In the United States, we are working with the U.S. Transportation Security Administration (“TSA”) towards air cargo certification. On March 27, 2018, we announced that the TRACER 1000 was accepted into TSA’s Air Cargo Screening Technology Qualification Test (“ACSQT”) and, on April 4, 2018, we announced that the TRACER 1000 was beginning testing with TSA for passenger screening at airports. On November 14, 2019, we announced that the TRACER 1000 had been selected by the TSA’s Innovation Task Force to conduct live checkpoint screening at Miami International Airport. With similar protocols as ECAC testing, we have received valuable feedback from all programs. Following ECAC certification and our early traction within the cargo market, testing for cargo security continued with the TSA. With the COVID-19 pandemic, all testing within the TSA was put on hold; however, we resumed cargo testing during the summer of 2020, and we subsequently announced on September 9, 2020 that the TRACER 1000 passed the non-detection testing portion of the TSA’s ACSQT. Due to continued delays caused by COVID-19, TSA cargo detection testing is ongoing but proceeding much more slowly than anticipated. As a result, efforts are primarily focused on our other opportunities. TSA cargo detection testing is the final step to be listed on the Air Cargo Screening Technology List (“ACSTL”) as an “approved” device. If approved, the TRACER 1000 will be approved for cargo sales in the United States.

AgLAB, an exclusive licensee of ATI for the agriculture market, has developed the AgLAB-1000™ series of mass spectrometers for use in the hemp and cannabis market with initial focus on optimizing yields in the extraction and distillation process. The AgLAB product line is a derivative of our core AMS Technology. The AMS Technology provides a significant competitive advantage due to its small size, rugged design, quick analysis, and ease of use. We continue to work with the market to refine our library and instrumentation.

~~BreathTech, an exclusive licensee of ATI for use in breath analysis, is developing the BreathTest-1000~~™~~, a breath analysis tool to screen for~~ VOC metabolites found in a person’s breath that could indicate they may have an infection, including COVID-19 or pneumonia. While vaccines have been deployed to prevent the transmission of COVID-19, only a fraction of the world has been vaccinated and new variants continue to pose a significant and evolving threat. New tools to aid in the battle against COVID-19 remain of the utmost importance to help defeat the disease, and BreathTech, in conjunction with Cleveland Clinic, are developing a quick and easy to use device to help prevent the further spread of the disease.

On February 1, 2022, BreathTech announced that it has hired Dr. Karim Sirgi, MD, MBA and FCAP as its Chief Science Officer. Dr. Sirgi is a pathologist, board certified in Anatomic, Clinical and Cytopathology, and has over 30 years of practice and leadership experience in private and academic pathology practices. We expect Dr. Sirgi will be key in the research and development and regulatory efforts at BreathTech and will help lead our partnership with Cleveland Clinic in the development of the BreathTest-1000.

~~In March 2020, the World Health Organization declared COVID-19 a global pandemic.~~

We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is uncertain and difficult to predict, as the disease and the responses that we, other businesses, and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it remains possible that it could cause a prolonged global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the economy as a whole. The magnitude and overall effectiveness of these actions have been somewhat positive, but continuing actions remain uncertain and pose some degree of risk.

To date, we have seen delays with respect to the TSA certification process and parts of our supply chain, particularly the impact of the global semiconductor and electronics shortage, which has now resulted in product pricing inflation. In addition, although passenger demand for air travel has rebounded, the overall recovery of the airline industry and ancillary services remains highly uncertain and is dependent upon, ~~among other things, the number of cases declining around the globe, public health impacts of~~

~~new COVID-19 variants, the continued administration of vaccines to unvaccinated populations, and the duration of immunity granted by vaccines.~~

We continue to manage production, to secure alternative supplies, and to take other proactive actions. We believe that we will be able to pass the inflation caused by raw materials shortages and increased shipping costs to our customers by increasing the price of our instruments. If supply chain shortages become more severe or longer term in nature, ~~our~~ ~~business and results of operations could be adversely impacted; however,~~ we ~~do not expect this issue to materially adversely affect our liquidity position. The long-term impact of the COVID-19 pandemic on~~ ~~our~~ ~~business may not be fully reflected until future periods.~~

We continue to evaluate the current and potential impact of the pandemic on our business, results of operations, and consolidated financial statements. We also continue to actively monitor developments and business conditions that may cause us to take further actions that alter business operations as may be required by applicable authorities or that we determine are in the best interests of our employees, customers, suppliers, and stockholders.

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates and assumptions are reviewed periodically. Actual results may differ from these estimates under different assumptions or conditions.

~~Three months ended December 31, 2021, compared to three months ended December 31, 2020~~:

~~Selected consolidated financial data for the quarters ended December 31, 2021, and 2020 is as follows:~~

Three Months Ended December 31,

(In thousands)

2021

2020

Revenue

$
561

$
130

Cost of revenue

441

128

Gross profit

120

2

Gross margin

21
%

2
%
Operating expenses:

Selling, general and administrative

1,728

803

Research and development

652

758

Total operating expenses

2,380

1,561

Loss from operations

(2,260
)

(1,559
)
Other income and (expense), net

80

(63
)
Income tax benefit

—

—

Net loss

$
(2,180
)

$
(1,622
)

~~Revenue~~ – ~~Total revenue significantly increased by $431 thousand during the second quarter of fiscal 2022, compared to the second quarter of fiscal 2021.~~ ~~In the second quarter of fiscal~~ ~~2022, revenue was comprised of sales related to our TRACER 1000 to an airport security checkpoint customer as well as to~~ ~~DHL (Deutsche Post AG). All of the revenue generated in the second quarter of fiscal 2021 was related to~~ ~~TRACER 1000 sales to~~ ~~DHL (Deutsche Post AG).~~

~~Cost of Revenue~~ – ~~Gross profit is comprised of revenue less cost of revenue. In the second quarters of fiscal 2022 and 2021, cost of revenue was~~ ~~comprised of labor, materials, shipping, and warranty reserve~~ related to the sale of TRACER 1000 units. Cost of revenue increased $313 thousand during the second quarter of fiscal 2022, compared to the second quarter of fiscal 2021, due to the increase in revenue described above. Gross margin increased by 19% in the second quarter fiscal 2022, compared to the second quarter of fiscal 2021, as we have increased production and benefited from associated volume discounts. Further, we have benefited from implementing specific enhancements to our technology.

~~Operating Expenses~~ – Operating expenses increased $819 thousand, or 52%, during the second quarter of fiscal 2022, compared to the second quarter of fiscal 2021. Significant changes to operating expenses include the following:

~~Income Taxes~~ –Income tax benefit did not change during the second quarter of fiscal 2022, compared to the second quarter of fiscal 2021. The realization of tax benefits depends on the existence of future taxable income. Pursuant to ~~Accounting Standards Codification (“ASC”)~~ ~~740 “Income Taxes”, a valuation allowance has been established on all of our deferred tax assets.~~

~~Six months ended December 31, 2021, compared to six months ended December 31, 2020~~:

~~Selected consolidated financial data for the six months ended December 31, 2021 and 2020 is as follows:~~

Six Months Ended
December 31,

(In thousands)

2021

2020

Revenue

$
748

$
270

Cost of revenue

616

241

Gross profit

132

29

Gross margin

18
%

11
%
Operating expenses:

Selling, general and administrative

3,154

1,729

Research and development

1,291

1,367

Disposal of corporate lease

—

544

Total operating expenses

4,445

3,640

Loss from operations

(4,313
)

(3,611
)
Other income and (expense), net

104

(122
)
Income tax benefit

—

—

Net loss

$
(4,209
)

$
(3,733
)

~~Revenue~~ – ~~Total revenue increased $478 thousand during the fiscal year 2022, compared fiscal year 2021.~~ I~~n fiscal year 2022,~~ ~~revenue was comprised of sales related to our TRACER 1000 to an airport security checkpoint customer as well as to~~ ~~DHL (Deutsche Post AG). In fiscal year 2021, all of our revenue was related to the~~ ~~sales of the TRACER 1000 to~~ ~~DHL (Deutsche Post AG).~~

~~Cost of Revenue~~ – ~~Gross profit is comprised of revenue less cost of revenue. In the six months ended December 31, 2021 and December 31, 2020, cost of revenue was~~ ~~comprised of labor, materials, shipping, warranty reserve, and overhead~~ allocation related to the sale of TRACER 1000 units. Cost of revenue increased $375 thousand during fiscal year 2022, compared to fiscal year 2021, due to the increase in revenue described above. Gross margin increased by 7% in the fiscal year 2022, compared to the fiscal year 2021, as we have increased production and benefited from associated volume discounts. Further, we have benefited from implementing specific enhancements to our technology.

~~Operating Expenses~~ – Operating expenses increased $805 thousand, or 22% during the six months ended December 31, 2021, compared to six months ended December 31, 2020. Significant changes to operating expenses include the following:

~~Income Taxes~~ –Income tax benefit did not change during the six months ended December 31, 2021, compared to the six months ended December 31, 2020. The realization of tax benefits depends on the existence of future taxable income. Pursuant to ASC 740 “Income Taxes”, a valuation allowance has been established on all of our deferred tax assets.

As of December 31, 2021, we held cash and cash equivalents of $30.2 million, and our working capital was approximately $56.9 million. As of June 30, 2021, we had cash and cash equivalents of $35.9 million, and our working capital was approximately $60.9 million. Cash and cash equivalents decreased $5.8 million as of December 31, 2021, compared to June 30, 2021, due to the partial repayment of the related party notes including accrued interest as well as continuing operating expenses.

Cash used in operating activities increased $1.0 million for the six months ended December 31, 2021, compared to the six months ended December 31, 2020, due to an increase in accounts receivable from sales of the TRACER 1000, receipt of an alternative minimum tax credit in the prior period, and a decrease in accounts payable.

Cash used in investing activities increased $248 thousand for the six months ended December 31, 2021, compared to the six months ended December 31, 2020, due to the addition of leasehold improvement assets related to our new R&D facility in Austin.

Cash used in financing activities was $2.0 million for the six months ended December 31, 2021, compared to cash provided by financing activities of $21.8 million for the six months ended December 31, 2020. This change was due to the partial repayment of the related party notes during the current period, compared to the net proceeds from sale of common stock of $21.8 million in the prior period.

Historically, our primary uses of cash have been to fund research and development, inventory, and selling, general and administrative expenses. During the fiscal year 2021, we successfully completed several public offerings of our common stock, raising net proceeds of approximately $67.6 million. We will continue to evaluate opportunities to further strengthen our liquidity, including selling the Company or a portion thereof, licensing some of our technology, raising additional funds through the capital markets, debt financing, equity financing, merging, or engaging in a strategic partnership. However, our ability to successfully effectuate any such transactions depends on operating and economic conditions, some of which are beyond our control. If additional capital is needed, we may not be able to obtain debt or equity financing on terms favorable to us, or at all. Based on current expectations, we believe we have sufficient liquidity to meet our cash flow needs during this fiscal year 2022 and the immediate future.

Our effective tax rate is 0% for income tax for the six months ended December 31, 2021, and we expect that our effective tax rate for the full fiscal year 2022 year will be 0%. Based on the weight of available evidence, including net cumulative losses and expected future losses, we have determined that it is more likely than not that our U.S. federal and state deferred tax assets will not be realized and therefore a full valuation allowance has been provided on the U.S. federal and state net deferred tax assets.

We recognize the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination. We currently have approximately $300 thousand of uncertain tax positions as of December 31, 2021, all of which are accounted as contra-deferred tax assets. The Company does not expect any significant changes to its uncertain tax positions in the coming 12 months.

~~There is $0 provision for income taxes during each of the three and six months ended December 31, 2021 and 2020.~~

~~We did not have any off-balance sheet arrangements as of December 31, 2021, or June 30, 2021.~~

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this Quarterly Report. Based on the evaluation and criteria of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There was no change in our internal control over financial reporting during our last fiscal quarter ended December 31, 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Further information regarding the Stein Action and the Section 205 Action is provided in the Schedule 14A proxy statement amendment and supplement filed by the Company with the Securities and Exchange Commission on April 29, 2021.

Our business, financial condition, results of operations, and cash flows may be impacted by a number of factors, many of which are beyond our control, including those set forth in our Form 10-K and our Form 10-Qs, the occurrence of any one of which could have a material adverse effect on our actual results.

~~There~~Except as set forth below, there have been no material changes to the risk factors and other cautionary statements described under the heading “Item 1A. Risk ~~Factors previously disclosed~~Factors” included in our Form 10-K for the fiscal year ~~2021 Form 10-K.~~ended June 30, 2022:

There can be no assurance that we will repurchase shares of our common stock at all or in any particular amounts.

The stock markets in general have experienced substantial price and trading fluctuations, which have resulted in volatility in the market prices of securities that often are unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the trading price of our common stock. Price volatility over a given period may also cause the average price at which we repurchase our own common stock to exceed the stock’s price at a given point in time. In addition, significant changes in the trading price of our common stock and our ability to access capital on terms favorable to us could impact our ability to repurchase shares of our common stock. The timing and amount of any repurchases will be determined by the Company’s management based on its evaluation of market conditions, capital allocation alternatives and other factors beyond our control. Our share repurchase program may be modified, suspended, extended or terminated by the Company at any time and without notice.

Exhibit No.	Description	Incorporation by Reference

3.1	Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware.	Exhibit 3.1 to Form 8-K filed on December 28, 2017.

3.2	Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 8-K filed with the Securities and Exchange Commission on December 28, 2017).	Exhibit 3.2 to Form 8-K filed on December 28, 2017.

3.3	Certificate of Designations of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware.	Exhibit 3.3 to Form 8-K filed on December 28, 2017.

3.4	~~Certificate of Designations of Series C Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019.~~	~~Exhibit 3.1 to Form 8-K filed on April 23, 2019.~~

~~3.5~~	Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Preferred Stock, as filed with the Delaware Secretary of State on April 17, 2019.	Exhibit 3.2 to Form 8-K filed on April 23, 2019.

~~3.6~~3.5	Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.	Exhibit 3.1 to Form 8-K filed on July 1, 2020.

~~3.7~~3.6	Certificate of Amendment to the Certificate of Incorporation of Astrotech Corporation.	Exhibit 3.1 to Form 8-K filed on October 12, 2021.

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.	Filed herewith.

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.	Filed herewith.

32.1	Certification pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934.	Furnished herewith.

101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.	Filed herewith.

101.SCH	Inline XBRL Taxonomy Extension Schema Document	Filed herewith.

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	Filed herewith.

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.

104	The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~December 31, 2021,~~September 30, 2022, has been formatted in Inline XBRL.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Page
PART I:	FINANCIAL INFORMATION	~~FINANCIAL INFORMATION~~3	3

ITEM 1.		CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)	3
ITEM 2.		MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	1820
ITEM 3.		QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	2325
ITEM 4.	CONTROLS AND PROCEDURES	~~CONTROLS AND PROCEDURES~~25

PART II:	OTHER INFORMATION	2326

ITEM 1.	LEGAL PROCEEDINGS		26
~~PART II:~~ITEM 1A.	RISK FACTORS	~~OTHER INFORMATION~~26	24

ITEM 1.2.		~~LEGAL PROCEEDINGS~~	24
~~ITEM 1A.~~		~~RISK FACTORS~~	24
~~ITEM 2.~~		UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	2426
ITEM 3.		DEFAULTS UPON SENIOR SECURITIES	2426
ITEM 4.	MINE SAFETY DISCLOSURES	~~MINE SAFETY DISCLOSURES~~26	24
ITEM 5.	OTHER INFORMATION	~~OTHER INFORMATION~~26	24
ITEM 6.	EXHIBITS	~~EXHIBITS~~27	25

(In thousands)	*Classification on the Condensed Consolidated Balance Sheet*	*September 30, 2022*
Assets:
Operating lease assets	Operating leases, right-of-use assets, net	$	140
Financing lease assets	Property and equipment, net		440
*Total lease assets*		$	580

Liabilities:
Current:
Operating lease obligations	Lease liabilities, current	$	98
Financing lease obligations	Lease liabilities, current		141
Non-current:
Operating lease obligations	Lease liabilities, non-current		64
Financing lease obligations	Lease liabilities, non-current		177
*Total lease liabilities*		$	480

(In thousands)	Classification on the Condensed Consolidated Balance Sheet	December 31, 2021
Assets:
Operating lease assets	Operating leases, right-of-use assets, net	$	206
Financing lease assets	Property and equipment, net		516
Total lease assets		$	722

Liabilities:
Current:
Operating lease obligations	Lease liabilities, current	$	92
Financing lease obligations	Lease liabilities, current		135
Non-current:
Operating lease obligations	Lease liabilities, non-current		138
Financing lease obligations	Lease liabilities, non-current		283
Total lease liabilities		$	648

Weighted-average remaining lease term (years):
Operating leases	1.6		~~2.4~~
Financing leases	2.2		~~3.0~~
Weighted-average discount rate:
Operating leases	6.4		~~6.4~~	%
Financing leases	5.3	%	~~5.3~~	%

(In thousands)	December 31, 2021			June 30, 2021			*September 30, 2022*			*June 30, 2022*
Furniture, fixtures, equipment & leasehold improvements	$	1,289		$	535		$	1,603		$	1,371
Software		264			315			209			264
Capital improvements in progress		—			187			240			242
Gross property and equipment		1,553			1,037			2,052			1,877
Accumulated depreciation and amortization		(683	)		(774	)		(702	)		(779	)
Property and equipment, net	$	870		$	263		$	1,350		$	1,098

	Preferred Stock
	Series D				Common Stock
	Number of Shares Outstanding		Amount		Number of Shares Outstanding		Amount		Treasury Stock Amount		Additional Paid-In Capital		Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity
Balance at June 30, 2021		281	$	—		49,451	$	190,641	$	—	$	77,971	$	(207,382	)	$	(23	)	$	61,207
Net change in available-for-sale marketable securities		—		—		—		—		—		—		—			(48	)		(48	)
Stock-based compensation		—		—		—		—		—		359		—			—			359
Net loss		—		—		—		—		—		—		(2,029	)		—			(2,029	)
Balance at September 30, 2021		281	$	—		49,451	$	190,641	$	—	$	78,330	$	(209,411	)	$	(71	)	$	59,489
Net change in available-for-sale marketable securities		—		—		—		—		—		—		—			(197	)		(197	)
Stock-based compensation		—		—		63		—		—		439		—			—			439
Net loss		—		—		—		—		—		—		(2,180	)		—			(2,180	)
Balance at December 31, 2021		281	$	—		49,514	$	190,641	$	—	$	78,769	$	(211,591	)	$	(268	)	$	57,551

	*September 30, 2022*
Available-for-Sale Securities	*Adjusted*		*Unrealized*		*Unrealized*			*Fair*
(In thousands)	*Cost*		*Gain*		*Loss*			*Value*
Mutual Funds - Corporate & Government Debt	$	19,997	$	—	$	(1,042	)	$	18,955
ETFs - Corporate & Government Debt		7,375		—		(498	)		6,877
Time Deposits		4,870		—		(27	)		4,843
Total	$	32,242	$	—	$	(1,567	)	$	30,675

	December 31, 2021
Available-for-Sale	Adjusted		Unrealized		Unrealized			Fair
(In thousands)	Cost		Gain		Loss			Value
Mutual Funds - Corporate & Government Debt	$	19,998	$	0	$	(179	)	$	19,819
ETFs - Corporate & Government Debt		7,376		0		(89	)		7,287
Total	$	27,374	$	0	$	(268	)	$	27,106

	June 30, 2021
Available-for-Sale	Adjusted		Unrealized		Unrealized			Fair
(In thousands)	Cost		Gain		Loss			Value
Mutual Funds - Corporate & Government Debt	$	19,998	$	0	$	(13	)	$	19,985
ETFs - Corporate & Government Debt		7,376		0		(10	)		7,366
Total	$	27,374	$	0	$	(23	)	$	27,351

	Carrying Value
	Short-Term Investments
(In thousands)	September 30, 2022		June 30, 2022
Mutual Funds - Corporate & Government Debt	$	18,955	$	19,191
ETFs - Corporate & Government Debt		6,877		6,982
Time Deposits - Maturities from 1-90 days		—		—
Time Deposits - Maturities from 91-360 days		4,843		—
Total	$	30,675	$	26,173

	Number of Shares Underlying Warrants (In thousands)		Weighted Average Exercise Price		Aggregate Fair Market Value at Issuance (In thousands)		Weighted Average Remaining Contractual Term (Years)						*Aggregate Fair*		*Weighted Average*
Outstanding June 30, 2021		2,393	$	2.40	$	3,747		4.63
									*Number of Shares*				*Market Value at*		*Remaining*
									*Underlying Warrants*		*Weighted Average*		*Issuance (In*		*Contractual Term*
									*(In thousands)*		*Exercise Price*		*thousands)*		*(Years)*
Outstanding June 30, 2022										2,393	$	2.40	$	3,747		3.60
Warrants issued		—		—		—		—		—		—		—		—
Warrants exercised		—		—		—		—		—		—		—		—
Warrants expired		—		—		—		—		—		—		—		—
Outstanding December 31, 2021		2,393	$	2.40	$	3,747		4.10
Outstanding September 30, 2022										2,393	$	2.40	$	3,747		3.35

	Shares (In thousands)			Weighted Average Exercise Price		*Shares*			*Weighted Average*
Outstanding at June 30, 2021		275		$	5.25
						*(In thousands)*			*Exercise Price*
Outstanding at June 30, 2022						$	1,029		$	1.35
Granted		—			—		155			0.44
Exercised		—			—		—			—
Canceled or expired		(122	)		4.96		(72	)		5.81
Outstanding at December 31, 2021		153		$	5.41
Outstanding at September 30, 2022						$	1,112		$	0.93

Range of exercise prices	Number Outstanding (In thousands)		Options Outstanding Weighted- Average Remaining Contractual Life (Years)		Weighted- Average Exercise Price		Number Exercisable (In thousands)		Options Exercisable Weighted- Average Exercise Price
$1.85 – 2.83		13		6.74	$	2.08		10	$	2.15
$5.00 – 5.85		88		5.36		5.55		88		5.55
$6.00 – 6.00		52		0.64		6.00		52		6.00
$1.85 – 6.00		153		3.87	$	5.41		150	$	5.49

			Options
			Outstanding						Options
			Weighted-						Exercisable
			Average		Weighted-				Weighted-
	Number		Remaining		Average		Number		Average
	Outstanding (In		Contractual		Exercise		Exercisable (In		Exercise
Range of exercise prices	thousands)		Life (Years)		Price		thousands)		Price
$0.44 - 0.64		1,031		9.60	$	0.61		—	$	—
$1.85 - 2.83		13		5.99		2.15		10		2.08
$5.30 - 5.85		68		4.61		5.63		68		5.63
$0.44- 5.85		1,112		9.25	$	0.93		77	$	5.18

	Shares (In thousands)			Weighted Average Grant-Date Fair Value					*Weighted*
Outstanding at June 30, 2021	$	2,023		$	2.05
									*Average*
						*Shares*			*Grant-Date*
						*(In thousands)*			*Fair Value*
Outstanding at June 30, 2022						$	2,276		$	1.30
Granted		—			—		—			—
Vested		(28	)		3.39		—			—
Canceled or expired		—			—		(2	)		2.02
Outstanding at December 31, 2021	$	1,995		$	2.03
Outstanding at September 30, 2022						$	2,274		$	1.30

	Three Months Ended September 30,
(In thousands)	2022			2021
Revenue	$	38		$	187
Cost of revenue		32			175
Gross profit		6			12
Gross margin		16	%		6	%
Operating expenses:
Selling, general and administrative		1,642			1,426
Research and development		1,129			639
Total operating expenses		2,771			2,065
Loss from operations		(2,765	)		(2,053	)
Other income and (expense), net		235			24
Income tax benefit		—			—
Net loss	$	(2,530	)	$	(2,029	)

	Three Months Ended December 31,
(In thousands)	2021			2020
Revenue	$	561		$	130
Cost of revenue		441			128
Gross profit		120			2
Gross margin		21	%		2	%
Operating expenses:
Selling, general and administrative		1,728			803
Research and development		652			758
Total operating expenses		2,380			1,561
Loss from operations		(2,260	)		(1,559	)
Other income and (expense), net		80			(63	)
Income tax benefit		—			—
Net loss	$	(2,180	)	$	(1,622	)

	Astrotech Corporation



Date: ~~February~~November 14, 2022	/s/ ~~Eric Stober~~Jaime Hinojosa
		~~Eric Stober~~Jaime Hinojosa
	Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting ~~Officer~~Officer)